Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study

Journal of the American Academy of Dermatology(2023)10.1016/j.jaad.2023.02.017Source: DataRank Database

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study is a research paper published in Journal of the American Academy of Dermatology (2023). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: greenTopics (15)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Guihong Wan ORCID,Nga Nguyen ORCID,Hannah Rashdan,Shijia Zhang ORCID,Wenxin Chen ORCID

Live enrichment

PubMed:36944564 PMC:PMC10796158

U.S. Department of Defense

Grant: W81XWH2110819

National Cancer Institute

Grant: U54-CA225088

NIAMS NIH HHS

Grant: K23 AR080791

NCI NIH HHS

Grant: U54 CA225088

NCI NIH HHS

Grant: L30 CA264747

Dermatology Foundation

National Institutes of Health

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10796158/pdf/nihms-1956695.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0190962223002682?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0190962223002682?httpAccept=text/plain

MeSH Terms

HumansHerpesvirus 1, HumanMelanomaBiological ProductsRetrospective StudiesCohort StudiesOncolytic VirotherapyImmune Checkpoint Inhibitors

Keywords

MelanomaImmunotherapySkin CancerTalimogene LaherparepvecImmune Checkpoint InhibitorsCutaneous ToxicitiesCutaneous Immune-related Adverse Events

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study

FAIR Checklist

Authors (14)

Funding (7 grants)

Open Access

Topics

Annotations (Europe PMC)